Katherine Harris, PhDVice President, Discovery at Amgen
Katherine Harris is Vice President of Discovery at Amgen where she leads Oncology Research at the Amgen Newark site, pursuing novel multi-specific molecules to modulate the anti-tumor immune response. Previously she served as Vice President of Discovery at Teneobio where she led the Discovery and Lead Optimization team in the development of multi-specific therapeutic antibodies. She joined Teneobio when the company started lab operations in 2015, playing a key role in the strategic direction of the company as well as building and managing a high-throughput antibody discovery platform. Prior to Teneobio, she worked at Active Motif and SwitchGear Genomics where she focused her efforts on developing a functional genomics platform for small molecule screening. Dr. Harris holds a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.